RU2252786C2 - Конструкции антител и хемокинов и их применение при иммунологических нарушениях - Google Patents

Конструкции антител и хемокинов и их применение при иммунологических нарушениях Download PDF

Info

Publication number
RU2252786C2
RU2252786C2 RU2003108885/15A RU2003108885A RU2252786C2 RU 2252786 C2 RU2252786 C2 RU 2252786C2 RU 2003108885/15 A RU2003108885/15 A RU 2003108885/15A RU 2003108885 A RU2003108885 A RU 2003108885A RU 2252786 C2 RU2252786 C2 RU 2252786C2
Authority
RU
Russia
Prior art keywords
antibody
construct
chemokine
ccr5
cells
Prior art date
Application number
RU2003108885/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2003108885A (ru
Inventor
Маттиас МАК (DE)
Маттиас МАК
Детлеф ШЛОЕНДОРФФ (DE)
Детлеф ШЛОЕНДОРФФ
Михаель ШПРИНГ (DE)
Михаель ШПРИНГ
Original Assignee
Микромет Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Микромет Аг filed Critical Микромет Аг
Publication of RU2003108885A publication Critical patent/RU2003108885A/ru
Application granted granted Critical
Publication of RU2252786C2 publication Critical patent/RU2252786C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
RU2003108885/15A 2000-09-08 2001-09-10 Конструкции антител и хемокинов и их применение при иммунологических нарушениях RU2252786C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00119694.8 2000-09-08
EP00119694 2000-09-08
US09/948,004 2001-09-05

Publications (2)

Publication Number Publication Date
RU2003108885A RU2003108885A (ru) 2004-08-27
RU2252786C2 true RU2252786C2 (ru) 2005-05-27

Family

ID=32842663

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003108885/15A RU2252786C2 (ru) 2000-09-08 2001-09-10 Конструкции антител и хемокинов и их применение при иммунологических нарушениях

Country Status (10)

Country Link
EP (1) EP1317284A2 (ja)
JP (1) JP2004508036A (ja)
AU (1) AU2002212225A1 (ja)
CA (1) CA2421842A1 (ja)
HU (1) HUP0300942A2 (ja)
NO (1) NO20031070L (ja)
PL (1) PL366062A1 (ja)
RU (1) RU2252786C2 (ja)
WO (1) WO2002020615A2 (ja)
ZA (1) ZA200301890B (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8058402B2 (en) 2006-08-28 2011-11-15 Kyowa Hakko Kirin Antagonistic human LIGHT-specific human monoclonal antibodies
US9175087B2 (en) 2007-08-29 2015-11-03 Sanofi Humanized anti-CXCR5 antibodies, derivatives thereof and their use
RU2609649C2 (ru) * 2010-06-28 2017-02-02 Универзитетсклиникум Фрайбург Блокада сигнализации ccl18 через ccr6 как терапевтический способ лечения при фиброзных заболеваниях и раке
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US11732044B2 (en) 2017-12-27 2023-08-22 Innovent Biologics (Suzhou) Co., Ltd. Anti-LAG-3 antibody and use thereof

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002360073A1 (en) * 2001-12-21 2003-07-09 Micromet Ag Mono-and dual chemokine/cytokine constructs
EP2336179A1 (en) 2002-11-08 2011-06-22 Ablynx N.V. Stabilized single domain antibodies
EP1937311A2 (en) 2005-09-30 2008-07-02 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Methods and compositions for modulating immune tolerance
AR065369A1 (es) 2007-02-19 2009-06-03 Novartis Ag Derivados de ciclohexil - amida del acido aril- carboxilico
EP4303236A3 (en) 2010-11-30 2024-03-20 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
CA2943943C (en) 2014-04-07 2023-01-10 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
SG11201609370QA (en) 2014-05-13 2016-12-29 Chugai Pharmaceutical Co Ltd T cell-redirected antigen-binding molecule for cells having immunosuppression function
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
WO2017210749A1 (en) * 2016-06-10 2017-12-14 Adelaide Research & Innovation Pty Ltd Methods and products for treating autoimmune diseases
EP4090348A4 (en) * 2020-01-13 2024-05-15 The Regents of The University of California METHODS FOR TREATING VIRAL INFECTIONS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004926A2 (en) * 1998-07-22 2000-02-03 Osprey Pharmaceuticals Limited Conjugates for treating inflammatory disorders and associated tissue damage
ATE286074T1 (de) * 1999-03-11 2005-01-15 Micromet Ag Gegen ccr5 gerichtete antikörperkonstrukte und ihre verwendung in der behandlung von autoimmunkrankheiten

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
L. WU et al. Interaction of chemokine receptor CCR5 with its ligands. J. Experim. Med. V.186, n.8, 1997, p.1373-1381. Антитела. Методы. Под ред. Д.Кэтти. Т.1. - М.: Мир, 1991, с.164-195. *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9771419B2 (en) 2006-08-28 2017-09-26 Kyowa Hakko Kirin Co., Limited Antagonistic human light-specific human monoclonal antibodies
US8461307B2 (en) 2006-08-28 2013-06-11 Kyowa Hakko Kirin Co., Limited Antagonistic human LIGHT-specific human monoclonal antibodies
US8974787B2 (en) 2006-08-28 2015-03-10 Kyowa Hakko Kirin Co., Limited Antagonistic human light-specific human monoclonal antibodies
US8058402B2 (en) 2006-08-28 2011-11-15 Kyowa Hakko Kirin Antagonistic human LIGHT-specific human monoclonal antibodies
US9175087B2 (en) 2007-08-29 2015-11-03 Sanofi Humanized anti-CXCR5 antibodies, derivatives thereof and their use
US9228019B2 (en) 2007-08-29 2016-01-05 Sanofi Humanized anti-CXCR5 antibodies, derivatives thereof and their use
US9243067B2 (en) 2007-08-29 2016-01-26 Sanofi Humanized anti-CXCR5 antibodies, derivatives thereof and their use
RU2571515C2 (ru) * 2007-08-29 2015-12-20 Санофи-Авентис Гуманизированные антитела к cxcr5, их производные и их применение
US9815902B2 (en) 2007-08-29 2017-11-14 Sanofi Humanized anti-CXCR5 antibodies, derivatives thereof and their uses
RU2609649C2 (ru) * 2010-06-28 2017-02-02 Универзитетсклиникум Фрайбург Блокада сигнализации ccl18 через ccr6 как терапевтический способ лечения при фиброзных заболеваниях и раке
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10525130B2 (en) 2012-03-26 2020-01-07 Sanofi Stable IGG4 based binding agent formulations
US11732044B2 (en) 2017-12-27 2023-08-22 Innovent Biologics (Suzhou) Co., Ltd. Anti-LAG-3 antibody and use thereof

Also Published As

Publication number Publication date
ZA200301890B (en) 2004-03-16
EP1317284A2 (en) 2003-06-11
NO20031070L (no) 2003-05-06
WO2002020615A3 (en) 2002-07-25
JP2004508036A (ja) 2004-03-18
CA2421842A1 (en) 2002-03-14
HUP0300942A2 (hu) 2003-09-29
WO2002020615A2 (en) 2002-03-14
AU2002212225A1 (en) 2002-03-22
NO20031070D0 (no) 2003-03-07
PL366062A1 (en) 2005-01-24

Similar Documents

Publication Publication Date Title
US6723538B2 (en) Bispecific antibody and chemokine receptor constructs
JP7250736B2 (ja) Ｂｃｍａおよびｃｄ３に対する結合分子
JP6845177B2 (ja) 長寿命ポリペプチド結合分子
RU2228202C2 (ru) Cd19xcd3-специфические полипептиды и их применение
RU2252786C2 (ru) Конструкции антител и хемокинов и их применение при иммунологических нарушениях
AU2006206064B2 (en) Anti-CCR2 antibodies and methods of use therefor
CN111432831A (zh) Il-2突变蛋白及其用途
Klarenbeek et al. Targeting chemokines and chemokine receptors with antibodies
EP1456241B1 (en) Mono-and dual anti-cd4-rantes chemokine/cytokine constructs
CA3218786A1 (en) C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same
CN116635422A (zh) 抗cd38抗体及其用途

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20080911